Biotransplant(BTRN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN)

BTRN 35.41

0.0%

Nov 26 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (545)	4/6/2000 2:33:00 PM
From: nigel bates	Read Replies (1) of 1475

Is this concerning the Edinburgh patent, or something different? newscientist.co.uk "Austin Smith of the University of Edinburgh and Hitoshi Niwa of Osaka University in Japan suspected that Oct-3/4--a transcription factor protein, which regulates gene activity--might be involved. They genetically engineered mouse ESCs to produce different levels of Oct-3/4. Their results showed that a finely tuned amount of the protein locks mouse ESCs into a state where they multiply without becoming specialised .... The team has licensed this technique to the biotech company Stem Cell Sciences in Australia" Sources: Nature Genetics (vol 24, p 372) Nature Biotechnology (vol 18, p 399) nig

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next